This. Prospectus will be published on the websites of the Luxembourg Stock Exchange (xxx.xxxxxx.xx) and the Issuer (xxx.xxxxxxx-xxxxx.xx). On the approval of this Prospectus as a prospectus for the purpose of Article 5.3 of the Prospectus Directive by the CSSF, notification of such approval will be made to the Italian National Stock Exchange and Companies Commission (Commissione Nazionale per le Società e la Borsa) ("CONSOB") in its capacity as the competent authority of the Republic of Italy.
This. Article also applies to any person who possesses inside information under circumstances other than those referred to in the first subparagraph where that person knows or ought to know that it is inside information.
This. Prospectus has been approved by the Commission de Surveillance du Secteur Financier of the Grand Duchy of Luxembourg (“Luxembourg”) (the “CSSF”) in its capacity as competent authority under the Luxembourg Act dated 10 July 2005 relating to prospectuses for securities (Loi du 10 juillet 2005 relative aux prospectus pour valeurs mobilières), as amended, (the “Luxembourg Prospectus Law”), which implements the Prospectus Directive into Luxembourg law. Pursuant to Article 7(7) of the Luxembourg Prospectus Law, by approving this Prospectus, the CSSF assumes no responsibility for, and gives no undertaking as to, the economic and financial soundness of the transaction and the quality or solvency of the Issuer. The Issuer has requested the CSSF to provide the competent authority in Italy, Commissione Nazionale per le Società e la Borsa (“CONSOB”) with a certificate of approval pursuant to Article 18 of the Prospectus Directive attesting that this Prospectus has been drawn up in accordance with the Luxembourg Prospectus Law (the “Notification”). Application has been made to Borsa Italiana S.p.A. (“Borsa Italiana”) for the Notes to be admitted to listing and trading on the Borsa Italiana’s regulated Mercato delle Obligazioni Telematico market (the “MOT”). The MOT is a regulated market for the purposes of Directive 2004/39/EC of the European Parliament and of the Council of 21 April 2004 on markets in financial instruments, as amended. Borsa Italiana has admitted the Notes to listing on the MOT with order n. 8121 dated 22 October 2015. The start date of official trading of the Notes on the MOT (the “Trading Start Date”) will be set by Borsa Italiana in accordance with Rule 2.4.3 of the Borsa Italiana rules and published on the Issuer’s Website and the Luxembourg Stock Exchange Website and released through the SDIR-NIS system of Borsa Italiana. The Trading Start Date shall correspond to the Issue Date. The aggregate principal amount of the Notes, the number of Notes sold and the proceeds of the Offering will be set out in a notice, which will be filed with the CSSF and published on the Issuer’s Website, the Luxembourg Stock Exchange Website and released through the SDIR-NIS system of Borsa Italiana no later than the third business day after the end of the Offering Period (the “Offering Results Notice”). The Notes will initially be represented by a temporary global note (the “Temporary Global Note”), without interest coupons, which will be deposited on or about the Issu...
More Definitions of This
This. Prospectus is to be read in conjunction with all documents which are deemed to be incorporated herein by reference (see “Information Incorporated by Reference”). This Prospectus should be read and construed on the basis that such documents are incorporated in and form part of this Prospectus. Investors should rely only on the information contained in this Prospectus. Neither the Issuer nor the Guarantor have authorised anyone to provide investors with different information. Neither the initial purchasers, nor the Issuer nor the Guarantor is making any offer of the Notes in any jurisdiction where the offer is not permitted. You should not assume that the information contained in this Prospectus is accurate as of any date other than the date on the cover of this Prospectus regardless of the time of delivery of this Prospectus or of any sale of the Notes. Neither the Issuer nor the Guarantor have authorised the making or provision of any representation or information regarding the Issuer, the Guarantor or the Notes other than as contained in this Prospectus or as approved for such purpose by the Issuer and the Guarantor. Any such representation or information should not be relied upon as having been authorised by the Issuer, the Guarantor or the Placement Agent. Neither the delivery of this Prospectus nor the offering, sale or delivery of any Note shall in any circumstances create any implication that the information contained herein concerning the Issuer, the Guarantor and/or its Group is correct at any time subsequent to the date hereof or that any other information supplied in connection with the offering of the Notes is correct as of any time subsequent to the date indicated in the document containing the same or that there has been no adverse change, or any event reasonably likely to involve any adverse change, in the condition (financial or otherwise) of the Issuer, the Guarantor and/or the Group since the date of this Prospectus. Neither this Prospectus nor any other information supplied in connection with the offering, sale or delivery of any Note (a) is intended to provide the basis of any credit or other evaluation or (b) should be considered as a recommendation by the Issuer, the Guarantor or the Placement Agent that any recipient of this Prospectus or any other information supplied in connection thereto should purchase any Note. Each investor contemplating purchasing any Note should make its own independent investigation of the financial condition...
This contract is governed by the laws of Italy and by the Economic Collective Agreement of 20 March 2002 governing commercial agency and representative agreements.
This. Contract is drawn up in n. 3 (three) copies of which 2 (two) stamped originals.
This. IPID is linked the policy n°10946422604 Avviso sul trattamento equo La presente Informativa sulla privacy descrive il metodo in cui la Compagnia assicurativa acquisisce e utilizza i dati personali dell’utente e altri soggetti quando la Compagnia assicurativa fornisce i propri servizi di assicurazione e riassicurazione. Le informazioni fornite dalla Compagnia assicurativa, insieme a informazioni mediche e altre informazioni ottenute dall’utente o da altri soggetti riguardo all’utente in connessione con la presente polizza, saranno utilizzate dalla Compagnia assicurativa al fine di determinare l’applicazione, il funzionamento dell’assicurazione (ciò include il processo di sottoscrizione, amministrazione, gestione dei sinistri, analisi relative all’assicurazione, riabilitazione e gestione di problematiche della clientela) e prevenzione e rilevamento di frodi. La Compagnia assicurativa potrebbe avere la necessità, ai sensi di legge, di acquisire determinati dati personali relativi all’utente o in conseguenza al rapporto contrattuale che la Compagnia assicurativa detiene con l’utente. La mancata comunicazione di tali informazioni potrebbe impedire o ritardare l’adempimento di tali obblighi. Le informazioni saranno condivise dalla Compagnia assicurativa per tali finalità con aziende del gruppo e terzi assicuratori, riassicuratori, intermediari assicurativi e prestatori di servizi. Tali soggetti potranno diventare titolari del trattamento in relazione alle informazioni personali dell’utente. Dato che la Compagnia assicurativa è una società operante a livello mondiale, la Compagnia assicurativa potrà trasferire le informazioni personali dell’utente all’esterno dello Spazio economico europeo per dette finalità. L’utente disporrà di determinati diritti riguardo alle informazioni personali, subordinatamente alla legislazione locale in vigore. Tali diritti includono i diritti a richiedere l’accesso, la rettifica, la cancellazione, la restrizione, l’obiezione e la ricezione dei propri dati personali in un formato elettronico idoneo e a trasmetterli a terzi (diritto di portabilità). Per qualsiasi domanda o dubbio riguardo alla modalità di utilizzo dei dati personali si prega di contattare: xxxxxxx.xxxxxxxxxxxxxxxxx@xxx.xx La Compagnia assicurativa si impegna a collaborare con l’utente al fine di ottenere una risoluzione equa di qualsiasi reclamo o problema in materia di privacy. Qualora, tuttavia, si ritenga che la Compagnia assicurativa non sia stata in grado di fornir...
This. O.U. will work at the Ospedale Policlinico San Xxxxxxx in Genoa and will responsible of the retrospective analysis aimed at identifying neo-adjuvant regimens of chemo/radio therapy able to induce TLS in the eventually resected tumor samples. Also, this O.U. will collect human samples of non-small-cell lung cancers and melanoma and the distribution of ILC subsets within the tumors will be investigated. This O.U. will focus on group 3 ILC (ILC3), which we already showed to be associated to TLS within lung cancers. In addition to flow cytometry and immune-histochemistry analysis, the O.U. will study the importance of ILC3 in the development of TLS by spatial multiomics analyses from tumor sections to be able to look at gene expressions variations inside and out of TLS, close or afar from ILC3, NK cells or g/d T cells. This should allow a better understanding of the role of innate lymphocytes in TLS development. The multiomics analyses will be performed using GeoMX spatial imager, a technology allowing spatial imaging of both mRNA and protein, allowing for a comprehensive study of the microenvironment. O.U. 2 The OU Bambino Gesù Children's Hospital in Rome will investigate the impact of chemo/radio therapy on the formation of tertiary lymphoid structures (TLS) in vivo. Mouse models of solid tumor by ectopic implantation of syngeneic tumor cells in immunocompetent mice (C57BL/6 strain) will be generated inoculating LLC cells for the lung adenocarcinoma model and MC38 and B16 respectively for colon adenocarcinoma and melanoma models. Tumor cells will be injected i.p. and the tumors allowed to establish. Mice will then undergo radiotherapy or chemotherapy (according to indications derived by the retrospective analyses performed in patient¿s samples by O.U.1 and the formation of TLS in the tumor will be evaluated. To understand the contribution of innate lymphocyte subsets on the TLS formation upon specific chemo/radio therapy, each innate lymphocyte subset will be specifically depleted. In addition to visualize immune cell distribution in lymphoid structures, tumor single cell suspensions will be analysed for frequency and LT-inducing properties of cell subsets in the immune infiltrate.
This. Prospectus also contains forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward looking statements as a result of various factors, including the risks described below and elsewhere in this Prospectus.
This. Prospectus also contains forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward looking statements as a result of various factors, including the risks described below and elsewhere in this Prospectus. The following are risk factors relating the Issuer and the Group (including the Future Guarantors) that may affect the Issuer’s and the Future Guarantors’ ability to fulfil their obligations under the Notes and the Future Guarantees, respectively. Since the Issuer, the Future Guarantors and their respective subsidiaries conduct the same business activities, we do not believe they are exposed to separate risks, except as otherwise noted.